Major changes will shape the clinical landscape in 2020. As medicine becomes more personalized, new methods for data collection, analysis and sharing will be designed. The integration of real and virtual data is therefore destined to recognize a broader section of the patient population in exciting developments for modern clinical trials.
New Ways of Managing Clinical Data
Sustainability has been the watchword of recent years, and it’s equally relevant to the management of clinical data. As much as 80% of all clinical data is single-use – collected and used only once. In the years ahead, reusable data will come to dominate the way clinical trials are conducted. Multiple data sources, including TQT studies, will combine with EHR data to provide analytics and insights and can be repurposed across the patient population.
Data management solutions will depend on flexibility and the ability to move from data management to clinical data science centered on patients as key contributors.
Synthetic Data Leads to Greater Efficiency
Integrating EHR data and clinical trial data, including TQT studies, has proven value in improving patient outcomes and discovering the best treatments, speeding diagnosis and subsequent treatment.
Going forward, synthetic data taken from real-world studies will be modeled for potential outcomes or specific patient groups. This data holds the potential to unlock new ways to identify optimized doses and mitigate side effects when determining therapeutic regimens or discovering synergies in therapies involving multiple drugs.
Innovative Techniques to Improve Trial Outcomes
90% of trial studies in the US currently experience significant delays due to low enrolment figures and patient retention – in fact, only 7% of trials currently meet their deadlines and targets. This is due to a number of factors, including geographical location, lack of awareness and poor engagement.
A number of initiatives, including hybridized trials with a digital component, community-based sites, and health trackers and apps, have been designed to address these issues by bringing clinical trials directly to the patients themselves. Improvements in data access and social engagement are designed to drive greater levels of trial awareness as part of initiatives to improve trial enrolment.
These new approaches will leverage the latest systems and advances to streamline efficiencies and are expected to drive more efficient and innovative frameworks for developing treatments for a range of patient needs.